|
|
 Previous Article | Table of Contents | Next Article 
Early deaths and anti-hemorrhagic treatments in acute promyelocytic
leukemia. A GIMEMA retrospective study in 268 consecutive patients [see
comments]
F Rodeghiero, G Avvisati, G Castaman, T Barbui and F Mandelli
Department of Hematology, San Bortolo Hospital, Vicenza, Italy.
The records of 268 consecutive patients with acute hypergranular
promyelocytic leukemia, treated at 29 Italian centers between January 1984
and December 1987, have been reviewed to assess the incidence of early
hemorrhagic deaths and the effectiveness of various antihemorrhagic
treatments. Three separate groups were considered: 94 patients were treated
with heparin, 67 with anti-fibrinolytics (tranexamic acid,
epsilon-aminocaproic acid, or aprotinin), and 107 with supportive therapy
alone. The overall incidence of early hemorrhagic death (within the first
10 days of treatment) was 9.4%, with no significant differences between the
various groups. Similarly, there were no differences in complete remission
rates or duration of survival. The consumption of packed red blood cells
and platelet concentrates was similar for two of the groups, and there was
a significantly greater use of platelet concentrates for heparin-treated
patients. High blast cell counts on the day of admission were significantly
associated with hemorrhagic death within the first 10 days. These counts,
plus high blast cell counts and low platelet counts, were associated with
death within 24 hours.
Volume 75,
Issue 11,
pp. 2112-2117,
06/01/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. de la Serna, P. Montesinos, E. Vellenga, C. Rayon, R. Parody, A. Leon, J. Esteve, J. M. Bergua, G. Milone, G. Deben, et al.
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin
Blood,
April 1, 2008;
111(7):
3395 - 3402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Falanga and F. R. Rickles
Management of Thrombohemorrhagic Syndromes (THS) in Hematologic Malignancies
Hematology,
January 1, 2007;
2007(1):
165 - 171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Douer, E. Estey, S. Santillana, J. M. Bennett, G. Lopez-Bernstein, K. Boehm, and T. Williams
Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid
Blood,
January 1, 2001;
97(1):
73 - 80.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Burnett, D. Grimwade, E. Solomon, K. Wheatley, and A. H. Goldstone
Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid: Result of the Randomized MRC Trial
Blood,
June 15, 1999;
93(12):
4131 - 4143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Falanga, R. Consonni, M. Marchetti, G. Locatelli, E. Garattini, C. G. Passerini, S.G. Gordon, and T. Barbui
Cancer Procoagulant and Tissue Factor Are Differently Modulated by All-trans-Retinoic Acid in Acute Promyelocytic Leukemia Cells
Blood,
July 1, 1998;
92(1):
143 - 151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Barbui, G. Finazzi, and A. Falanga
The Impact of All-trans-Retinoic Acid on the Coagulopathy of Acute Promyelocytic Leukemia
Blood,
May 1, 1998;
91(9):
3093 - 3102.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Baglin
Fortnightly Review: Disseminated intravascular coagulation: diagnosis and treatment
BMJ,
March 16, 1996;
312(7032):
683 - 686.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. P. Warrell, H. de The, Z.-Y. Wang, and L. Degos
Acute Promyelocytic Leukemia
N. Engl. J. Med.,
July 15, 1993;
329(3):
177 - 189.
[Full Text]
|
|
|
|
|
